DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1780)

Crohn's Disease | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US) - Pediatric

Crohn's Disease | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US) - Pediatric

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Conventional agents (e.g., immunosuppressants, 5-ASAs) have long been used to treat pediatric Crohn’s disease (CD). Among the TNF-α inhibitors, Janssen/Merck’s Remicade and AbbVie/Eisai’s Humira are the most commonly used biologics in moderate to severe pediatric CD. The newer drugs (i.e., Takeda’s Entyvio and Janssen’s Stelara), approved for adult CD, offer alternative treatment options, especially for TNF-α refractory patients; however, these drugs are not approved in pediatric CD. Still, given the limited treatment options for pediatric CD patients who fail TNF-α inhibitors, physicians may turn to these novel therapies for some patients. Indeed, the availability of these newer agents will likely make the treatment landscape more complex.

QUESTIONS ANSWERED:

  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed pediatric CD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric CD patients?
  • How have Entyvio and Stelara been integrated into the treatment algorithm?
  • What proportion of pediatric CD patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of pediatric CD patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
  • What are the product-level compliance and persistency rates among drug-treated pediatric patients with CD?

PRODUCT DESCRIPTION: 

Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.

Already a Client? Log in to access this report.

  • Pub Date: May 2018
  • Author(s): Qinghui Yu
  • Qinghui Yu is a business insights analyst at Decision Resources Group. She has authored market research reports analyzing market trends in autoimmune diseases. Prior to joining Decision Resources Group, Dr. Yu worked as a senior analyst for a life science consulting firm, where she worked on a range of projects providing strategic growth advice to clients in life science industries. Her other experience includes assessing the scientific and commercial viability of technologies developed in academic labs while working as a fellow at Columbia Technology ;Qinghui Yu holds a from Columbia ;

Become a DRG client

Recent reports:
You may also be interested in: